Nothing Special   »   [go: up one dir, main page]

Das et al., 2021 - Google Patents

Are we ready for covid–19 vaccines?–A general side effects overview

Das et al., 2021

View PDF
Document ID
8985097975914089659
Author
Das L
Meghana A
Paul P
Ghosh S
Publication year
Publication venue
Journal of Current Medical Research and Opinion

External Links

Snippet

A vaccine is considered to be one of the best options in public health safety, specifically when there is no effective vaccine available against that infectious disease. 6 Classic vaccine development often takes years, but developing a vaccine for the prevention of Covid …
Continue reading at www.cmro.in (PDF) (other versions)

Classifications

    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/32Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06QDATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10Services
    • G06Q50/22Health care, e.g. hospitals; Social work

Similar Documents

Publication Publication Date Title
Ivers et al. COVID-19: global health equity in pandemic response
Riva et al. Pandemic fear and literature: observations from Jack London’s The Scarlet Plague
Casadevall et al. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities
Fauci Emerging and reemerging infectious diseases: the perpetual challenge
Stern et al. The history of vaccines and immunization: familiar patterns, new challenges
Jogalekar et al. Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions
Bitanihirwe Monitoring and managing mental health in the wake of Ebola
Kirenga et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda
Das et al. Are we ready for covid–19 vaccines?–A general side effects overview
Ambrose et al. An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2–17 years
Bearden et al. An outbreak of the 2009 influenza a (H1N1) virus in a children’s hospital
Juan-Giner et al. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial
Koch Ebola, quarantine, and the scale of ethics
Tweed et al. Syndemic health crises—The growing role of National Public Health Institutes in shaping a coordinated response
Guharoy et al. Smallpox: clinical features, prevention, and management
Bouare et al. COVID-19: A pluralistic and integrated approach for efficient management of the pandemic
Hutchinson et al. COVID-19 Variants of Concern in Australia, September 2020-April 2021.
Afolabi Vaccination
Boushab et al. Two cases of delayed diagnosis of leprosy in Mauritania
Sevak et al. Review of novel corona virus disease (Covid-19) in India
Sah et al. Re-emergence of Sudan ebolavirus after a decade: new challenge to Ebola control
Escott et al. Don't forget the bigger picture: The impact of societal issues on a community‐based TB programme, Swaziland
Akech et al. COVID-19 Vaccination Uptake and Self-Reported Side Effects among Healthcare Workers in Mbale City Eastern Uganda
Marcus et al. Vaccination During the COVID-19 Pandemic: What Nurses Need To Know.
Datta et al. Randomization amid a pandemic–a critical appraisal regarding convalescent plasma therapy clinical trials for COVID‐19 patients